Does TAGRAXOFUSP-ERZS Cause Capillary leak syndrome? 110 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 110 reports of Capillary leak syndrome have been filed in association with TAGRAXOFUSP-ERZS. This represents 25.1% of all adverse event reports for TAGRAXOFUSP-ERZS.
110
Reports of Capillary leak syndrome with TAGRAXOFUSP-ERZS
25.1%
of all TAGRAXOFUSP-ERZS reports
35
Deaths
55
Hospitalizations
How Dangerous Is Capillary leak syndrome From TAGRAXOFUSP-ERZS?
Of the 110 reports, 35 (31.8%) resulted in death, 55 (50.0%) required hospitalization, and 13 (11.8%) were considered life-threatening.
Is Capillary leak syndrome Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TAGRAXOFUSP-ERZS. However, 110 reports have been filed with the FAERS database.
What Other Side Effects Does TAGRAXOFUSP-ERZS Cause?
Pyrexia (45)
Death (36)
Disease progression (33)
Thrombocytopenia (26)
Blood albumin decreased (24)
Acute kidney injury (23)
Off label use (23)
Weight increased (22)
Transaminases increased (21)
Tumour lysis syndrome (21)
What Other Drugs Cause Capillary leak syndrome?
GEMCITABINE (134)
PACLITAXEL (97)
CYCLOPHOSPHAMIDE (86)
DOCETAXEL (81)
CYTARABINE (68)
METHOTREXATE (65)
NIVOLUMAB (61)
RITUXIMAB (58)
FILGRASTIM (52)
FLUDARABINE (52)
Which TAGRAXOFUSP-ERZS Alternatives Have Lower Capillary leak syndrome Risk?
TAGRAXOFUSP-ERZS vs TAHOR
TAGRAXOFUSP-ERZS vs TALAZOPARIB
TAGRAXOFUSP-ERZS vs TALC
TAGRAXOFUSP-ERZS vs TALIGLUCERASE ALFA
TAGRAXOFUSP-ERZS vs TALIMOGENE LAHERPAREPVEC